In a news release from March 2021, international pharmaceutical company the Menarini Group shared that it had joined a partnership with Nippon Shinyaku Co., Ltd. ("Nippon") to develop and commercialize…
According to a story from Newswise, the early results of a recent phase 1/2 clinical trial have revealed the potential of an experimental treatment that was being tested for blastic…
According to a story from PR Newswire, the pharmaceutical and diagnostics company The Menarini Group recently announced that its drug tagraxofsup (marketed as Elzonris) has a received a positive opinion…
Written by Paul Pavao The power of a cancer patient's good attitude cannot be over-emphasized. Within the first week of chemo a nurse was willing to tell me, "We can…
A new treatment was recently tested for blastic plasmacytoid dendritic cell neoplasm (BPDCN). A recent article in MD Anderson News points out that in the U.S., five hundred to…
According to a story from First World Pharma, the biopharmaceutical company Mustang Bio, Inc. recently announced that the US Food and Drug Administration (FDA) has approved their investigational new drug…
According to a story from Specialty Pharmacy Times, data from a Phase II clinical trial has recently been released which suggests that the drug tagraxofsup is a useful treatment in…
Big news out of the FDA last week! Alexion Pharmaceuticals got approval for ALXN1210 for paroxysmal nocturnal hemoglobinuria, or PNH, which will now be sold as Ultomiris, while Stemline got approval…
According to a story from OncLive, the results of a Phase II trial for an experimental drug called SL-401 showed that the product could be a potentially effective treatment for…
A Biologics License Application for ElzonrisTM (also known as tagraxofusp and SL-401) for the treatment of blastic plasmacytoid dendritic cell neoplasm has been accepted for filing by the United States FDA.…
Results from research into an experimental therapy called SL-401 for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm have been shared at the Congress of the European Haematology…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
